Healthcare Industry News: Shionogi
News Release - June 30, 2008
Tobira Therapeutics Inc. Announces Senior Management Team
Senior management team possessing over 130 years of cumulative expertisePRINCETON, N.J. and SAN DIEGO, June 30 (HSMN NewsFeed) -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to the research and product discovery against life-threatening and life-altering infectious diseases, today announced the organization of the company's senior management team. Tobira Therapeutics has been led since its inception in 2006 by James Sapirstein, RPh, MBA as Chief Executive Officer and President. Joining James is Sandra Palleja, MD, Executive Vice-President and Chief Medical Officer, Angeline Shashlo, RPh, Senior Vice-President Regulatory Affairs and Quality Assurance, and Jay Rheingold, PhD, Vice-President Chemistry Manufacturing and Controls. These additions continue to build the management team with world-class pharmaceutical development experts. "With this senior management team Tobira Therapeutics has more than 130 years of combined pharmaceutical experience, with the majority focused in biotech companies or HIV compounds. We are perfectly positioned to bring novel molecules to market that will play an important role in the treatment of HIV infection".
Dr. Palleja is the Chief Medical Officer, responsible for the overall clinical development of the Tobira Therapeutics portfolio. Sandra joined Tobira from Shionogi USA, where she lead numerous clinical programs as Vice President of Clinical Development in several therapeutic categories including an HIV joint venture with GSK. Prior to her years at Shionogi, Sandra gained additional experience from both Triangle Pharmaceutics and Hoffman-LaRoche, where she helped develop a variety of antivirals for HIV and hepatitis including FTC, DAPD, ganciclovir, and saquinavir. Prior to her career in industry, she was the Director of the Infectious Diseases Clinic at St. Vincent's Hospital and Medical Center of New York City during the mid to late 90's. Prior to her years at St. Vincent's, Sandra was an Associate Professor of Medicine, served as the Primary Care Liason to the AIDS Team at the Albert Einstein College of Medicine and Bronx Municipal Hospital Center. From 1989-1993, she also served as Consultant to the AIDS Institute, NYSDOH and the Federally Funded Ryan White Title III Program. She earned her MD from Boston University School of Medicine.
Ms. Shashlo joined Tobira from Incyte Corporation where she held a similar role as the VP of Regulatory Affairs and Quality Assurance. Prior to Incyte, Angie spent several years working with start-up companies such as Genaera, Vitagen and Ligand in a variety of roles including Project Management. Angeline spent many years working for larger pharmaceutical companies such as Wyeth and Upjohn during the first half of her 25-year career in positions of increasing responsibility. Angie received her Bachelor of Science in Pharmacy from the University of Michigan.
Dr. Rheingold brings over 29 years of experience in new product scale-up, formulation development and manufacturing to Tobira Therapeutics. Jay has successfully brought over 25 products to market during his tenure at Lederle, Hoffman-LaRoche, Bristol-Myers Squibb and Organon pharmaceutical companies. He received his doctorate in Pharmaceutical Sciences from the University of Connecticut. Jay joins Tobira from Barrier Therapeutics, where he held the position of Vice-President.
About Tobira Therapeutics, Inc.
Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.
Source: Tobira Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
